Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients

被引:1
|
作者
Wang Li
Mei Xue-Ling
机构
[1] Allergy and Clinical Immunology Centre
[2] Beijing 100050
[3] Beijing Friendship Hospital
[4] Capital Medical University
[5] China
[6] Department of Dermatology
关键词
Mortality; Relative Risk; Stevens-Johnson Syndrome; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap; Toxic Epidermal Necrolysis;
D O I
暂无
中图分类号
R758.6 [原因未明的皮肤病];
学科分类号
100206 ;
摘要
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases with high mortality rates. This study was designed to analyze the pathogenic factors, clinical manifestations, complications, treatment, and prognosis of SJS/TEN and to explore the differences between surviving and deceased patients.Methods: SJS/TEN patients admitted to Beijing Friendship Hospital from January 2006 to December 2015 were included in the study. Patients’ data were retrospectively analyzed. Comparative studies were performed on the survival group and the deceased group, and Fisher’s exact probability test was used for statistical analysis.Results: Among the 88 patients included, 40 (45.5%) were male with a mean age of 45 ± 18 years. Forty-eight (54.5%) had SJS, 34 (38.6%) had SJS/TEN, and 6 (6.8%) had TEN. Fifty-three (60.2%) cases were caused by medications, mainly antibiotics (n = 24) followed by traditional Chinese medicines (n = 7). Forty-two cases (47.7%) developed visceral damage. Eighty-two patients improved or recovered and were discharged from hospital, and six patients died. Comparative studies on the survival group and the deceased group showed that the presence of malignant tumor (χ2 = 27.969,P < 0.001), connective tissue diseases (χ2 = 9.187,P = 0.002), previous abnormal liver/kidney functions (χ2 = 6.006,P = 0.014), heart rate >100 times/min (χ2 = 6.347,P = 0.012), detached skin area >20% (χ2 = 5.594,P = 0.018), concurrent mucosal involvement at the mouth, eyes, and external genitals (χ2 = 4.945,P = 0.026), subsequent accompanying liver/kidney damage (χ2 = 11.839,P = 0.001, andχ2 = 36.302,P < 0.001, respectively), and SCORTEN score >2 (χ2 = 37.148,P < 0.001) increased the risk of death.Conclusions: SJS/TEN is mainly caused by medications, and nearly half of patients develop visceral damage. Multiple factors increase the mortality risk.
引用
收藏
页码:1062 / 1068
页数:7
相关论文
共 50 条
  • [41] Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis
    Valeyrie-Allanore, L.
    Wolkenstein, P.
    Brochard, L.
    Ortonne, N.
    Maitre, B.
    Revuz, J.
    Bagot, M.
    Roujeau, J. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (04) : 847 - 853
  • [42] Stevens-Johnson syndrome and toxic epidermal necrolysis: A fresh look at an old foe
    Kaimal, Sowmya
    Lobo, Carol
    Narayan, Girish
    Augustine, Mary
    INDIAN JOURNAL OF DERMATOLOGY, 2023, 68 (01) : 34 - 40
  • [43] Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review
    Arora, Rohini
    Pande, Rajesh K.
    Panwar, Shikha
    Gupta, Vivek
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2021, 25 (05) : 575 - 579
  • [44] Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan
    Hsieh, Ming-Hsiu
    Watanabe, Tomoya
    Aihara, Michiko
    FRONTIERS IN MEDICINE, 2021, 8
  • [45] A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
    Antoon, James W.
    Goldman, Jennifer L.
    Shah, Samir S.
    Lee, Brian
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (01) : 244 - +
  • [46] Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update
    Jennifer L. Coias
    Laila F. Abbas
    Adela R. Cardones
    Current Dermatology Reports, 2019, 8 : 219 - 233
  • [47] Causative Drugs of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Israel
    Maggio, Nicola
    Firer, Maria
    Zaid, Huda
    Bederovsky, Yana
    Aboukaoud, Mohammed
    Gandelman-Marton, Revital
    Noyman, Iris
    Ekstein, Dana
    Blatt, Ilan
    Marom, Eli
    Schwartzberg, Eyal
    Israel, Shoshana
    Ingber, Arieh
    Brautbar, Chaim
    Eyal, Sara
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (07) : 823 - 829
  • [48] Aceclofenac induced Stevens-Johnson/toxic epidermal necrolysis overlap syndrome
    Ameen, Kaderthambi Hajamohideen Nooru
    Pinninti, Rakesh
    Jami, Swathi
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2013, 4 (01) : 69 - 71
  • [49] Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    Cheng, Lin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [50] Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine
    Kirchhof, Mark G.
    Miliszewski, Monica A.
    Sikora, Sheena
    Papp, Anthony
    Dutz, Jan P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (05) : 941 - 947